Collaboration between the FDA and industry is essential to foster innovation in Alzheimer’s treatments
(By
As the Food and Drug Administration moves closer to a decision about whether to approve a promising new Alzheimer’s treatment, the collaboration between scientists, regulators, and business leaders that produced this encouraging drug has come under fire as a “black eye” for the FDA that “dangerously compromised” its objectivity. This unfortunate charge misconstrues the drug development process and the indispensable partnerships that are needed to deliver new treatments. Continue reading the article here…
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org